Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries

Ibrahim N. Muhsen, Shahrukh K. Hashmi, Dietger Niederweiser, Nicolaus Kroeger, Samir Agrawal, Marcelo C. Pasquini, Yoshiko Atsuta, Karen K. Ballen, Adriana Seber, Wael Saber, Mohamed A. Kharfan-Dabaja, Walid Rasheed, Shinichiro Okamoto, Nandita Khera, William A. Wood, Mickey B.C. Koh, Hildegard Greinix, Yoshihisa Kodera, Jeff Szer, Mary M. HorowitzDaniel Weisdorf, Mahmoud Aljurf

Research output: Contribution to journalReview article

Abstract

Health care costs attributed to biologics have increased exponentially in the recent years, thus biosimilars offer a possible solution to limit costs while maintaining safety and efficacy. Reducing expenditure is vital to health care especially in developing countries where affordability and access to health care is a major challenge. We discuss the opportunities and the challenges of biosimilars in the field of hematopoietic cell transplantation (HCT) in low- and lower-middle income countries. Developing countries can potentially invest in the forecasted costs reduction by utilizing biosimilars. This can be used to decrease the costs of procedures such as HCT, which is a rapidly growing field in many developing regions. The introduction of biosimilars in the developing regions faces many challenges which include, but are not limited to: legal and regulatory issues, lack of research infrastructure, and the presence of educational barriers. Thus, collaborative efforts are needed to ensure an effective and safe introduction of biosimilars into low- and lower-middle income countries.

Original languageEnglish (US)
JournalBone Marrow Transplantation
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Biosimilar Pharmaceuticals
Transplantation
Bone Marrow
Transplants
Cell Transplantation
Costs and Cost Analysis
Developing Countries
Health Services Accessibility
Health Expenditures
Biological Products
Health Care Costs
Delivery of Health Care
Safety

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective : the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries. / Muhsen, Ibrahim N.; Hashmi, Shahrukh K.; Niederweiser, Dietger; Kroeger, Nicolaus; Agrawal, Samir; Pasquini, Marcelo C.; Atsuta, Yoshiko; Ballen, Karen K.; Seber, Adriana; Saber, Wael; Kharfan-Dabaja, Mohamed A.; Rasheed, Walid; Okamoto, Shinichiro; Khera, Nandita; Wood, William A.; Koh, Mickey B.C.; Greinix, Hildegard; Kodera, Yoshihisa; Szer, Jeff; Horowitz, Mary M.; Weisdorf, Daniel; Aljurf, Mahmoud.

In: Bone Marrow Transplantation, 01.01.2019.

Research output: Contribution to journalReview article

Muhsen, IN, Hashmi, SK, Niederweiser, D, Kroeger, N, Agrawal, S, Pasquini, MC, Atsuta, Y, Ballen, KK, Seber, A, Saber, W, Kharfan-Dabaja, MA, Rasheed, W, Okamoto, S, Khera, N, Wood, WA, Koh, MBC, Greinix, H, Kodera, Y, Szer, J, Horowitz, MM, Weisdorf, D & Aljurf, M 2019, 'Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries', Bone Marrow Transplantation. https://doi.org/10.1038/s41409-019-0658-2
Muhsen, Ibrahim N. ; Hashmi, Shahrukh K. ; Niederweiser, Dietger ; Kroeger, Nicolaus ; Agrawal, Samir ; Pasquini, Marcelo C. ; Atsuta, Yoshiko ; Ballen, Karen K. ; Seber, Adriana ; Saber, Wael ; Kharfan-Dabaja, Mohamed A. ; Rasheed, Walid ; Okamoto, Shinichiro ; Khera, Nandita ; Wood, William A. ; Koh, Mickey B.C. ; Greinix, Hildegard ; Kodera, Yoshihisa ; Szer, Jeff ; Horowitz, Mary M. ; Weisdorf, Daniel ; Aljurf, Mahmoud. / Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective : the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries. In: Bone Marrow Transplantation. 2019.
@article{518a0a0ae1a44f7db7cd9031c4cc3156,
title = "Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries",
abstract = "Health care costs attributed to biologics have increased exponentially in the recent years, thus biosimilars offer a possible solution to limit costs while maintaining safety and efficacy. Reducing expenditure is vital to health care especially in developing countries where affordability and access to health care is a major challenge. We discuss the opportunities and the challenges of biosimilars in the field of hematopoietic cell transplantation (HCT) in low- and lower-middle income countries. Developing countries can potentially invest in the forecasted costs reduction by utilizing biosimilars. This can be used to decrease the costs of procedures such as HCT, which is a rapidly growing field in many developing regions. The introduction of biosimilars in the developing regions faces many challenges which include, but are not limited to: legal and regulatory issues, lack of research infrastructure, and the presence of educational barriers. Thus, collaborative efforts are needed to ensure an effective and safe introduction of biosimilars into low- and lower-middle income countries.",
author = "Muhsen, {Ibrahim N.} and Hashmi, {Shahrukh K.} and Dietger Niederweiser and Nicolaus Kroeger and Samir Agrawal and Pasquini, {Marcelo C.} and Yoshiko Atsuta and Ballen, {Karen K.} and Adriana Seber and Wael Saber and Kharfan-Dabaja, {Mohamed A.} and Walid Rasheed and Shinichiro Okamoto and Nandita Khera and Wood, {William A.} and Koh, {Mickey B.C.} and Hildegard Greinix and Yoshihisa Kodera and Jeff Szer and Horowitz, {Mary M.} and Daniel Weisdorf and Mahmoud Aljurf",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41409-019-0658-2",
language = "English (US)",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective

T2 - the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries

AU - Muhsen, Ibrahim N.

AU - Hashmi, Shahrukh K.

AU - Niederweiser, Dietger

AU - Kroeger, Nicolaus

AU - Agrawal, Samir

AU - Pasquini, Marcelo C.

AU - Atsuta, Yoshiko

AU - Ballen, Karen K.

AU - Seber, Adriana

AU - Saber, Wael

AU - Kharfan-Dabaja, Mohamed A.

AU - Rasheed, Walid

AU - Okamoto, Shinichiro

AU - Khera, Nandita

AU - Wood, William A.

AU - Koh, Mickey B.C.

AU - Greinix, Hildegard

AU - Kodera, Yoshihisa

AU - Szer, Jeff

AU - Horowitz, Mary M.

AU - Weisdorf, Daniel

AU - Aljurf, Mahmoud

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Health care costs attributed to biologics have increased exponentially in the recent years, thus biosimilars offer a possible solution to limit costs while maintaining safety and efficacy. Reducing expenditure is vital to health care especially in developing countries where affordability and access to health care is a major challenge. We discuss the opportunities and the challenges of biosimilars in the field of hematopoietic cell transplantation (HCT) in low- and lower-middle income countries. Developing countries can potentially invest in the forecasted costs reduction by utilizing biosimilars. This can be used to decrease the costs of procedures such as HCT, which is a rapidly growing field in many developing regions. The introduction of biosimilars in the developing regions faces many challenges which include, but are not limited to: legal and regulatory issues, lack of research infrastructure, and the presence of educational barriers. Thus, collaborative efforts are needed to ensure an effective and safe introduction of biosimilars into low- and lower-middle income countries.

AB - Health care costs attributed to biologics have increased exponentially in the recent years, thus biosimilars offer a possible solution to limit costs while maintaining safety and efficacy. Reducing expenditure is vital to health care especially in developing countries where affordability and access to health care is a major challenge. We discuss the opportunities and the challenges of biosimilars in the field of hematopoietic cell transplantation (HCT) in low- and lower-middle income countries. Developing countries can potentially invest in the forecasted costs reduction by utilizing biosimilars. This can be used to decrease the costs of procedures such as HCT, which is a rapidly growing field in many developing regions. The introduction of biosimilars in the developing regions faces many challenges which include, but are not limited to: legal and regulatory issues, lack of research infrastructure, and the presence of educational barriers. Thus, collaborative efforts are needed to ensure an effective and safe introduction of biosimilars into low- and lower-middle income countries.

UR - http://www.scopus.com/inward/record.url?scp=85073779919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073779919&partnerID=8YFLogxK

U2 - 10.1038/s41409-019-0658-2

DO - 10.1038/s41409-019-0658-2

M3 - Review article

C2 - 31484992

AN - SCOPUS:85073779919

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

ER -